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Background
Bronchial thermoplasty is a bronchoscopic procedure to reduce the mass of airway 
smooth muscle and attenuate bronchoconstriction. We examined the effect of 
bronchial thermoplasty on the control of moderate or severe persistent asthma.
Methods
We randomly assigned 112 subjects who had been treated with inhaled corticoste-
roids and long-acting β2-adrenergic agonists (LABA) and in whom asthma control 
was impaired when the LABA were withdrawn to either bronchial thermoplasty or 
a control group. The primary outcome was the frequency of mild exacerbations, 
calculated during three scheduled 2-week periods of abstinence from LABA at 3, 6, 
and 12 months. Airflow, airway responsiveness, asthma symptoms, the number of 
symptom-free days, use of rescue medication, and scores on the Asthma Quality of 
Life Questionnaire (AQLQ) and the Asthma Control Questionnaire (ACQ) were also 
assessed.
Results
The mean rate of mild exacerbations, as compared with baseline, was reduced in 
the bronchial-thermoplasty group but was unchanged in the control group (change 
in frequency per subject per week, −0.16±0.37 vs. 0.04±0.29; P = 0.005). At 12 months, 
there were significantly greater improvements in the bronchial-thermoplasty group 
than in the control group in the morning peak expiratory flow (39.3±48.7 vs. 
8.5±44.2 liters per minute), scores on the AQLQ (1.3±1.0 vs. 0.6±1.1) and ACQ 
(reduction, 1.2±1.0 vs. 0.5±1.0), the percentage of symptom-free days (40.6±39.7 vs. 
17.0±37.9), and symptom scores (reduction, 1.9±2.1 vs. 0.7±2.5) while fewer puffs 
of rescue medication were required. Values for airway responsiveness and forced 
expiratory volume in 1 second did not differ significantly between the two groups. 
Adverse events immediately after treatment were more common in the bronchial-
thermoplasty group than in the control group but were similar during the period 
from 6 weeks to 12 months after treatment.
Conclusions
Bronchial thermoplasty in subjects with moderate or severe asthma results in an 
improvement in asthma control. (ClinicalTrials.gov number, NCT00214526.)
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Many of the variable symptoms of asthma are thought to be due to the contraction of airway smooth muscle, 
leading to bronchoconstriction.1,2 Increased air-
way smooth-muscle mass is a characteristic fea-
ture of asthma, particularly in persons with se-
vere or fatal asthma.3,4 Bronchial thermoplasty is 
a novel intervention in which controlled thermal 
energy is delivered to the airway wall during a 
series of bronchoscopies, resulting in a prolonged 
reduction of airway smooth-muscle mass.5 In pre-
vious studies, we determined the amount and du-
ration of energy to be delivered that result in 
modest thermal injury.5,6 The treatment in hu-
mans of airways between 3 and 10 mm in diam-
eter led to clinically meaningful reductions in 
muscle-mediated narrowing of the airway and to 
the improvement of asthma symptoms.7,8 We re-
port the results of the yearlong randomized, 
controlled Asthma Intervention Research (AIR) 
Trial, which examined the efficacy and safety of 
bronchial thermoplasty as a treatment for mod-
erate or severe persistent asthma.
Me thods
Subjects
Persons 18 to 65 years of age were eligible for en-
rollment if they had moderate or severe persistent 
asthma, defined according to the guidelines of 
the Global Initiative for Asthma,9 requiring daily 
therapy with inhaled corticosteroids equivalent 
to a dose of 200 μg or more of beclomethasone 
and long-acting β2-adrenergic agonists (LABA), at 
a dose of 100 μg or more of salmeterol (Serevent, 
GlaxoSmithKline) or the equivalent, to maintain 
reasonable asthma control. Inclusion criteria 
were airf low obstruction, assessed as a prebron-
chodilator forced expiratory volume in 1 second 
(FEV1) of 60 to 85% of the predicted value, and 
airway hyperresponsiveness, defined by a pro-
vocative concentration of methacholine required 
to lower the FEV1 by 20% (PC20) of less than 8 mg 
per milliliter, as well as stable asthma during the 
6 weeks before enrollment. Stable asthma was 
defined as an absence of unscheduled physician 
visits for asthma care, unchanged use of asthma 
medication for maintenance therapy, and stable 
use of rescue medication (4 puffs or fewer of a 
short-acting bronchodilator at a dose of 100 μg 
per puff delivered by a metered-dose inhaler [al-
buterol or the equivalent]) during 24 hours for 
symptom relief.
One other criterion in addition to fulfilling 
the definition of moderate or severe asthma was 
worsening asthma control after abstention from 
LABA at baseline for 2 weeks, documented by 
either an increase of at least 0.5 in the score on 
the Asthma Control Questionnaire (ACQ)10 (on 
a scale of 0 to 6, with higher numbers indicating 
worse control), or a decline of 5% in the average 
morning peak expiratory flow (PEF) during the 
second week of abstinence, as compared with the 
mean morning PEF during the week immedi-
ately before LABA therapy was withdrawn. Sub-
jects were excluded if they had had three or 
more lower respiratory tract infections requir-
ing antibiotics during the previous 12 months 
or a respiratory tract infection within the previ-
ous 6 weeks.
Study Design
This randomized, controlled trial was conducted 
at 11 centers in four countries. During the 4-week 
baseline period, subjects continued to receive main-
tenance therapy with inhaled corticosteroids and 
LABA for the first 2 weeks, and LABA were then 
withheld for the next 2 weeks. Therapy with in-
haled corticosteroids and LABA was resumed for 
the treatment period, which lasted for at least 6 
weeks and usually no more than 9 weeks, with a 
subsequent 12-month follow-up period. The 
study design is shown in Figure 1. All subjects 
were seen in follow-up at 3 months while receiv-
ing treatment with inhaled corticosteroids and 
LABA. They were asked to refrain from using 
LABA after this point, unless they had a severe 
exacerbation (an event requiring treatment with 
oral corticosteroids, as judged by the investiga-
tor, or a decrease in the morning PEF, for 1 or 
more days, of more than 30% below the average 
baseline morning PEF recorded during the week 
immediately preceding withdrawal from LABA 
therapy), or if they were judged by the investiga-
tor to have poor asthma control that required the 
resumption of LABA. For those subjects whose 
asthma could be controlled without LABA, evalu-
ations were performed after 6 and 12 months of 
treatment with inhaled corticosteroids alone. 
Subjects who needed to resume LABA therapy be-
The New England Journal of Medicine 
Downloaded from nejm.org on January 9, 2017. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
Bronchial Thermoplasty in Asthma
n engl j med 356;13 www.nejm.org march 29, 2007 1329
33p9
240 Subjects underwent screening
172 Received maintenance therapy
(corticosteroids and LABA) at baseline
112 Had LABA withdrawn
for 2 wk
3-Mo follow-up visit 
(during treatment with cortico-
steroids and LABA)
AUTHOR:
FIGURE:
JOB: ISSUE:
4-C
H/T
RETAKE
SIZE
ICM
CASE
EMail Line
H/T
Combo
Revised
AUTHOR, PLEASE NOTE: 
Figure has been redrawn and type has been reset.
Please check carefully.
REG F
Enon
1st
2nd
3rd
Cox
1 of 3
03-29-07
ARTIST: ts
35613
56 Were assigned to bronchial
thermoplasty
56 Were assigned to
a control group
52 Were included in analysis
    3 Withdrew consent
    1 Was lost to follow-up 
48 Were included in analysis
    4 Withdrew consent 
    4 Were lost to follow-up 
49 Were included in analysis
    3 Had incomplete testing
47 Were included in analysis
    1 Had incomplete testing
20 Resumed LABA therapy 25 Resumed LABA therapy
50 Were included in analysis
  2 Had incomplete testing
48 Were included in analysis
  1 Had incomplete testing
28 Resumed LABA therapy24 Resumed LABA therapy
49 Were included in analysis
  3 Had incomplete testing
46 Were included in analysis
  3 Had incomplete testing
Outcomes assessment at 3 mo
and 2 wk (LABA withdrawn)
6-Mo follow-up visit
LABA withdrawn
12-Mo follow-up visit
Outcomes assessment
at 12 mo and 2 wk
52 Were included in analysis 49 Were included in analysis  Maintenance therapy resumed
Outcomes assessment at 6 mo
and 2 wk
LABA withdrawn
LABA resumed, if needed
LABA resumed, if needed
Figure 1. Study Design.
Seven subjects (three in the bronchial-thermoplasty group and four in the control group) withdrew consent before the 
3-month follow-up visit. Six subjects (two in the bronchial-thermoplasty group and four in the control group) withdrew 
consent for reasons unrelated to the study, and one subject in the bronchial-thermoplasty group refused to abstain 
from long-acting β2-agonist (LABA) after the follow-up visit at 6 weeks. Inhaled corticosteroids alone were continued 
only if the treatment was tolerated. Visits 1 through 3 after baseline and the 6-week follow-up visit are not shown.
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fore the visits at 6 and 12 months were evaluated 
at those assessment points after withdrawal from 
LABA therapy for 2 weeks.
The study protocol was approved by local or 
regional ethics review boards at all study sites be-
fore the enrollment of any subjects. All subjects 
provided written informed consent. The study be-
gan in November 2002, and the 12-month follow-
up period was completed for all subjects by No-
vember 2005. An independent data and safety 
monitoring board oversaw the study.
Randomization
Eligible subjects were assigned to treatment with 
inhaled corticosteroids plus LABA (control group) 
or to treatment with bronchial thermoplasty in 
addition to inhaled corticosteroids and LABA 
(bronchial-thermoplasty group) in blocks of four 
at each center. The randomization code was com-
puter-generated centrally and provided to the study 
sites in separate envelopes. Investigators were un-
aware of the block size.
Treatment Period
Subjects assigned to the bronchial-thermoplasty 
group underwent three bronchoscopy procedures 
performed with the use of the Alair system (Asth-
matx) at intervals of approximately 3 weeks. Dur-
ing the procedure, they were under either general 
anesthesia or conscious sedation, as previously de-
scribed.5,8 A video showing part of an actual pro-
cedure is in the Supplementary Appendix, avail-
able with the full text of this article at www.nejm.
org. Control subjects had three treatment visits at 
intervals of 3 weeks for clinical review and spiro-
metric assessment and received a systemic cortico-
steroid similar to that administered to subjects 
in the bronchial-thermoplasty group.
Follow-Up Period
All subjects in the two groups were seen 2 weeks 
after each treatment visit. After the last treatment 
visit (designated as time 0), clinic visits were 
scheduled at 6 weeks and at 3, 6, and 12 months. 
Subjects were contacted by telephone on days 1 and 
7 after each treatment visit and monthly after the 
visit at month 3.
Outcome Measures
The primary outcome was the difference between 
the two groups in the change in the rate of mild 
exacerbations between baseline and later time 
points. Exacerbations, ascertained from daily dia-
ries in which subjects recorded events, were de-
fined as at least one of the following occurrences 
on 2 consecutive days: a reduction in the morning 
PEF of at least 20% below the average value (based 
on the PEF recorded during the week immediately 
preceding the withdrawal of LABA at baseline), 
the need for more than three additional puffs of 
rescue medication exceeding the average use dur-
ing the week immediately preceding the with-
drawal of LABA at baseline, or nocturnal awak-
ening caused by asthma symptoms.11 Only events 
occurring during the 2-week periods of absti-
nence from LABA, according to the study proto-
col, at 3, 6, and 12 months were used to calculate 
the rates of mild and severe exacerbations.
All subjects kept a daily diary from the begin-
ning of the baseline period to the visit at month 
6, and for a 4-week period before the visit at 
month 12. The data recorded in the diaries were 
used to assess changes in the PEF, the use of 
rescue medication, the number of symptom-free 
days, and the symptom score. The symptom score 
was the total of the individual scores (on a scale 
of 0 to 3, with higher numbers indicating more 
frequent or more severe symptoms or both) for 
nighttime wheezing and cough and daytime 
wheezing, cough, breathlessness, and sputum pro-
duction. These six individual scores were summed 
to yield a maximum possible score of 18. A symp-
tom-free day was defined as a day during which 
the symptom score was 0 and there was no night-
time awakening. The ACQ consists of six ques-
tions and the measurement of prebronchodilator 
FEV1, and responses are scored on a scale of 0 to 
6, with lower numbers indicating better asthma 
control. The minimal important change in the 
score is thought to be 0.5.12 The Asthma Quality 
of Life Questionnaire (AQLQ) consists of 32 items 
covering asthma-related symptoms and limitations 
during the 2 weeks preceding administration of 
the questionnaire, and responses are scored on 
a scale of 1 to 7, with higher numbers indicating a 
better quality of life. The minimal important 
change in the score is thought to be 0.5.13 For 
details of the outcome measures, see the Supple-
mentary Appendix.
Monitoring Adverse Events
At each visit and during each telephone call, sub-
jects were asked by research staff about potential 
adverse events, and their daily diaries were exam-
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ined by study personnel to ensure complete report-
ing of events. Adverse events were classified as 
respiratory or nonrespiratory events and were re-
ported at baseline and for the treatment period 
and the post-treatment period.
Statistical Analysis
The statistical analysis was performed on an in-
tention-to-treat basis and included those subjects 
who completed at least one bronchoscopy session 
or treatment visit. The study was powered to de-
tect differences between the two groups in the 
change from baseline to later time points. There 
was no imputation of missing data. Frequencies 
of adverse events were compared with the use of 
Fisher’s exact test. For continuous variables, sta-
tistical significance was determined with the use 
of Student’s t-test, and for categorical variables, 
statistical significance was determined with the 
use of the Cochran−Mantel−Haenszel test. P values 
of less than 0.05 were considered to indicate sta-
tistical significance. Data are reported as means 
(±SD), and all reported P values are two-sided, 
unless otherwise indicated.
The study was designed with more than 90% 
power to detect a difference of eight mild exac-
erbations per subject per year between the two 
groups with the use of a two-tailed t-test. Exacer-
bation rates and secondary outcomes were ana-
lyzed on the basis of the change from the base-
line period (the 2-week period during which the 
subjects were treated with inhaled corticosteroids 
alone) to the 2-week periods at 3, 6, and 12 
months during which they were treated with in-
haled corticosteroids alone (Fig. 1). For the analy-
sis of the effects of bronchial thermoplasty in ad-
dition to usual care, at 3 months, the relevant 
baseline was treatment with inhaled corticoste-
roids plus LABA. Data for all subjects were in-
cluded in the safety analyses.
The protocol was designed by a committee of 
academic authors and employees of the sponsor, 
with comment in specific areas from an advi-
sory board. The database was managed and all 
analyses requested by the investigators were per-
formed by QST Consultations. The manuscript 
was written by the corresponding author, with 
contributions from all coauthors and selected 
employees of the sponsor, and was reviewed by 
the external advisory board. The final manuscript 
was prepared by the corresponding author, with-
out limitation by the sponsor. All the authors 
vouch for the accuracy and completeness of the 
reported data.
R esult s
Baseline Characteristics of the Subjects
Of 240 subjects who underwent screening, 68 
did not fulfill all the entry criteria on assessment 
during the run-in period and 60 did not complete 
the phase of withdrawal from LABA (i.e., could not 
tolerate withdrawal, did not have deterioration, 
or withdrew consent). The remaining 112 subjects 
underwent randomization, and 56 subjects were 
assigned to each of the two study groups (Fig. 1). 
Outcomes for the effect of bronchial thermoplasty 
in addition to usual care were assessed at 3 months 
for 52 subjects in the bronchial-thermoplasty group 
and 48 control subjects; complete data after 12 
months of follow-up were available for 52 subjects 
in the bronchial-thermoplasty group and 49 in the 
control group (Fig. 1). The baseline demographic 
characteristics of the two groups were similar (Ta-
ble 1). For the statistical comparisons, baseline 
means were calculated only for subjects for whom 
follow-up data were available.
Exacerbations
Twelve months after the last study treatment, the 
mean number of mild exacerbations in the bron-
chial-thermoplasty group was 0.18±0.31 per sub-
ject per week, as compared with 0.35±0.32 at base-
line. The number of mild exacerbations in the 
control group was 0.31±0.46 per subject per week, 
as compared with 0.28±0.31 at baseline. The dif-
ference between the two groups in the change 
from baseline was significant at 3 months and at 
12 months (P = 0.03 for both comparisons) but 
not at 6 months (Fig. 2). As compared with base-
line, the average number of exacerbations during 
the 2-week periods at 3, 6, and 12 months when 
subjects in the two groups were treated with 
inhaled corticosteroids alone was reduced in the 
bronchial-thermoplasty group but was not signifi-
cantly changed in the control group (−0.16±0.37 
vs. 0.04±0.29 per subject per week, P = 0.005 for 
the comparison between the groups). Analysis 
with the use of the Wilcoxon rank-sum method 
also showed a significant difference between the 
groups (P = 0.01). This finding can be extrapolated 
to approximately 10 fewer mild exacerbations per 
subject per year in the bronchial-thermoplasty 
group.
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Twelve months after the last study treatment, 
the mean number of severe exacerbations in the 
bronchial-thermoplasty group was 0.01±0.08 per 
subject per week, as compared with 0.07±0.18 at 
baseline. The number of severe exacerbations in 
the control group was 0.06±0.24 per subject per 
week, as compared with 0.09±0.31 at baseline. 
The difference between the two groups in the 
change from baseline was not significant at any 
time point (Fig. 2).
Changes in the secondary outcomes (airflow, 
airway hyperresponsiveness, use of rescue medi-
cation, asthma symptoms, and scores on the 
AQLQ and ACQ) in the subjects receiving usual 
Table 1. Demographic and Clinical Characteristics of Subjects Completing One or More Treatment Visits.*
Characteristic
Bronchial-Thermoplasty 
Group Control Group
No. of subjects 55 54
Age — yr 39.36±11.18 41.65±11.35
Sex — no. (%)
Male 24 (44) 23 (43)
Female 31 (56) 31 (57)
Race or ethnic group — no. (%)†
White 51 (93) 50 (93)
Black 3 (5) 2 (4)
Asian 1 (2) 2 (4)
PC20 geometric mean — mg/ml (95% CI) 0.25 (0.16–0.40) 0.35 (0.23–0.52)
Prebronchodilator FEV1 — % predicted 72.65±10.41 76.12±9.28
Dose of study medication — µg
Inhaled corticosteroid — beclomethasone or the equivalent‡ 1351±963 1264±916
Median 1000.00 1000.00
LABA — salmeterol or the equivalent§ 111.3±35.9 105.8±30.8
Asthma severity — no.¶
Moderate persistent 21 26
Severe persistent 34 28
Seasonal allergies present — no. (%) 34 (62) 35 (65)
Deterioration of asthma control after 2 weeks of abstinence  
from LABA — no. (%)
Increase in score on ACQ of at least 0.5 17 (31) 12 (22)
Decline in morning PEF of at least 5% 15 (27) 14 (26)
Both increase and decrease 21 (38) 25 (46)
Neither increase nor decrease‖ 2 (4) 3 (6)
* Subjects in the bronchial-thermoplasty group were treated with bronchial thermoplasty, inhaled corticosteroids, and long-
acting β2-agonists (LABA), and those in the control group were treated with inhaled corticosteroids and LABA. Plus–minus 
values are means ±SD. Percentages may not sum to 100 because of rounding. PC20 denotes provocative concentration 
of methacholine required to lower the forced expiratory volume in 1 second (FEV1) by 20%, CI confidence interval, ACQ 
Asthma Control Questionnaire, and PEF peak expiratory flow.
† Race or ethnic group was self-reported.
‡ The dose of any other inhaled corticosteroid was converted to the equivalent dose of beclomethasone.
§ The dose of any other LABA was converted to the equivalent dose of salmeterol.
¶ For each subject, asthma was categorized as moderate and persistent or severe and persistent on the basis of the assess-
ment of the subject’s FEV1 value and the frequency of symptoms with the dose of maintenance therapy, according to the 
2004 guidelines of the Global Initiative for Asthma for these measures.9
‖ Three subjects in the control group and two in the bronchial-thermoplasty group did not fulfill either of these criteria, 
and their inclusion in the study was considered a deviation from the protocol. There was no significant difference in  
the outcomes when these subjects were excluded.
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care at 3 months and when LABA were withdrawn 
at 3, 6, and 12 months are shown in Figure 3. 
For further data on secondary outcomes, see the 
Supplementary Appendix.
High-Dose Inhaled Corticosteroids
In a post hoc analysis, data for a subgroup of 
subjects requiring high maintenance doses of in-
haled corticosteroids (>1000 μg of beclometha-
sone or the equivalent) at baseline were analyzed 
separately and showed greater differences between 
the control group and the bronchial-thermoplasty 
group. Data on this analysis are in the Supplemen-
tary Appendix.
Adverse Events
There was an increase in adverse respiratory 
events in subjects undergoing bronchial thermo-
plasty immediately after the procedure, with a re-
turn to baseline values during the post-treatment 
period. During the treatment period, there were 
407 adverse respiratory events, of which 69% were 
mild, 28% were moderate, and 3% were severe. 
In the control group there were 106 adverse respi-
ratory events, of which 69% were mild, 30% were 
moderate, and 1% were severe. The most frequent-
ly observed adverse events during the treatment 
period are listed in Table 2. In the bronchial-
thermoplasty group, the majority of the adverse 
events occurred within 1 day after the procedure 
and resolved an average of 7 days after the onset 
of the event.
Hospitalizations for adverse respiratory events 
during the treatment period were more frequent 
in the bronchial-thermoplasty group (four subjects 
required a total of six hospitalizations) than in 
the control group (two subjects required one hos-
pitalization each). Four of the hospitalizations of 
subjects in the bronchial-thermoplasty group were 
for exacerbation of asthma (one within 1 day 
after treatment, two 30 days after treatment, and 
one 85 days after treatment), one was for partial 
collapse of the left lower lobe (2 days after treat-
ment), and one was for pleurisy (43 days after 
treatment).
During the post-treatment period, the propor-
tion of subjects with adverse respiratory events 
was similar in the two groups (Table 2). The rate 
of hospitalization for respiratory events was low 
during this period and did not differ significantly 
between the two groups: three subjects in the 
bronchial-thermoplasty group required hospital-
ization — one for chest infection and two for 
asthma exacerbation — and two subjects in the 
control group required a total of three hospital-
izations for increased asthma symptoms. There 
were no deaths during the study.
Although there were variations among the 
study centers in the size of the treatment effect 
and the number of adverse events, there was no 
obvious relationship between the investigators’ 
experience with bronchial thermoplasty or the 
numbers of subjects treated and the outcomes or 
adverse events. One additional hospitalization for 
an adverse respiratory event occurred 14 months 
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Figure 2. Rates of Mild and Severe Exacerbations per Subject per Week.
Mean values are shown for all subjects receiving inhaled corticosteroids 
alone for whom data were available at the given time points. Asterisks indi-
cate a statistically significant difference in the mean change from baseline 
between the two groups, and I bars represent the standard errors. P = 0.03 
for the comparison between subjects in the two groups treated with inhaled 
corticosteroids alone at 3 months and at 12 months.
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after bronchial thermoplasty in a subject who 
had undergone the procedure uneventfully and 
had completed the trial with normal spirometric 
values and good asthma control (score on the 
ACQ, 0.2; symptom score, 0), but who subsequent-
ly underwent resection for an abscess in a left 
upper lobe. Histologic examination did not reveal 
obstruction or any other potentially contributory 
abnormality in the airways as a result of thermo-
plasty. (For information on the follow-up in the 
bronchial-thermoplasty group after completion of 
the study, see the Supplementary Appendix.)
Discussion
This randomized, controlled study examined the 
efficacy and safety of bronchial thermoplasty in 
subjects with moderate or severe persistent asthma. 
The study design was based on the hypothesis 
that if bronchial thermoplasty were beneficial, 
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Figure 3 (on facing pages). Measures of Asthma Control at Baseline and during Follow-up.
Mean values are shown for all subjects for whom data were available at the given time points. P values are for comparisons of the mean 
change from baseline between the two groups. I bars represent standard errors. In Panel C, airway responsiveness was measured while 
subjects were treated with inhaled corticosteroids (ICS) but long-acting β2-agonists (LABA) were withheld. The severity of symptoms 
was scored on a scale of 0 to 18, with lower scores indicating fewer or less severe symptoms, or both. Responses to the Asthma Quality 
of Life Questionnaire (AQLQ) are scored on a scale of 1 to 7, with higher numbers indicating a better quality of life. The minimal important 
difference is thought to be 0.5.13 Responses to the Asthma Control Questionnaire (ACQ) are scored on a scale of 0 to 6, with lower num-
bers indicating better asthma control. The minimal important difference is thought to be 0.5.12 PEF denotes peak expiratory flow, FEV1 
forced expiratory volume in 1 second, and PC20 a provocative concentration of methacholine required to lower the FEV1 by 20%.
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then in subjects treated with bronchial thermo-
plasty, as compared with control subjects, asth-
ma control would be improved when treatment 
with LABA was discontinued. Although the ben-
efits of bronchial thermoplasty were obvious 
when LABA were withdrawn, they were also ob-
served at 3 months, when all subjects in the two 
study groups were still receiving LABA (Fig. 3). 
Among subjects treated with inhaled corticoste-
roids alone, bronchial thermoplasty reduced the 
frequency of mild exacerbations at a rate equiva-
lent to 10 exacerbations per subject per year and 
provided 86 additional symptom-free days per 
subject per year. These improvements were 
achieved during a period in which the use of res-
cue medication was reduced in the bronchial-
thermoplasty group, as compared with the con-
trol group.
The effect of bronchial thermoplasty was evi-
dent 3 months after the procedure. The improve-
ments in objective and subject-centered outcomes 
did not diminish over the course of the study, 
and the outcomes assessed at 1 year showed the 
same degree of improvement as at 3 months. In 
a preliminary, nonrandomized study, we found 
that the benefits of bronchial thermoplasty per-
sisted at 2 years.8 Thus, although the duration of 
the effect of bronchial thermoplasty remains un-
certain, in this study the benefit appeared to per-
sist at 1 year.
Treatment with bronchial thermoplasty was 
associated with adverse events related primarily 
to worsening of asthma symptoms during the 
period immediately after treatment. Although 
the frequency of adverse events was similar in 
the two groups at 6 weeks to 1 year after bron-
chial thermoplasty, studies of larger numbers of 
patients and with a longer follow-up will be need-
ed to rule out less common adverse events than 
those identified in this study.
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The interpretation of our results is confounded 
by the nonblinded study design; this limitation is 
important, given that bronchial thermoplasty is 
a procedure that may increase the potential for 
a strong placebo effect.14-16 However, the magni-
tude and persistence of the effects of the inter-
vention observed are probably greater than what 
could be attributed to placebo alone. For exam-
ple, a within-group change of 0.5 in scores on the 
AQLQ is considered clinically significant,13 and 
we found a between-group difference of 0.69 at 
12 months. Of the outcomes reported, perhaps 
the two that are least susceptible to bias are the 
morning PEF, since it was measured daily for 
Table 2. Adverse Respiratory Events.*
Event Bronchial-Thermoplasty Group Control Group P Value†
Frequency  
of Event 
Subjects with 
Event
Frequency  
of Event 
Subjects with 
Event
percent
Treatment period plus 6 wk
Dyspnea 19.9 70.9 21.7 33.3 <0.001
Wheezing 17.0 61.8 7.5 13.0 <0.001
Cough 16.0 52.7 11.3 18.5 <0.001
Chest discomfort 10.3 47.3 18.9 20.4 0.004
Night awakenings 9.8 40.0 4.7 9.3 <0.001
Productive cough 8.6 40.0 8.5 11.1 <0.001
Upper respiratory tract infection 2.5 12.7 1.9 3.7 0.16
Bronchial irritation 2.0 9.1 0 0 0.06
Nasal congestion 2.0 12.7 10.4 11.1 1.00
Sputum discolored 1.7 10.9 0 0 0.03
Dry mouth 1.2 3.6 0 0 0.50
Abnormal chest sound 1.0 5.5 0 0 0.24
Bronchospasm 1.0 7.3 0 0 0.12
Post-treatment period (6 wk–12 mo)
Dyspnea 22.1 49.1 26.4 53.8 0.70
Cough 15.4 38.2 13.0 36.5 1.00
Nasal congestion 9.6 27.3 10.1 26.9 1.00
Wheezing 9.6 29.1 8.7 23.1 0.52
Productive cough 9.2 23.6 7.7 23.1 1.00
Chest discomfort 6.7 21.8 8.2 13.5 0.32
Upper respiratory tract infection 6.3 18.2 2.9 5.8 0.07
Night awakenings 3.3 12.7 3.4 9.6 0.76
Pharyngolaryngeal pain 3.3 10.9 3.8 13.5 0.77
Nasopharyngitis 2.9 10.9 1.4 5.8 0.49
Respiratory tract congestion 2.5 9.1 1.0 3.8 0.44
Respiratory tract infection 2.5 9.1 5.8 17.3 0.26
Bronchitis 1.3 1.8 0 0 1.00
Throat irritation 1.3 3.6 1.0 3.8 1.00
* Subjects were asked about adverse events at each office visit and during telephone calls. Only adverse events occurring 
in the bronchial-thermoplasty group at a frequency of 1.0% or greater are listed.
† For the comparison between the two groups of the number of subjects reporting an adverse event, P values were calcu-
lated with the use of Fisher’s exact test.
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most of the study period, and the number of mild 
exacerbations per subject per week, since these 
were counted after the study had ended by a stat-
istician who reviewed the data in the daily diaries, 
according to predetermined criteria. The increase 
in the morning PEF value of 39 liters per minute 
from baseline to 12 months among subjects 
treated with bronchial thermoplasty (between-
group difference, 31 liters per minute) exceeded 
the change seen in placebo groups in other trials 
involving patients with asthma (range, –22 to 17 
liters per minute).17-21 Our data showing poten-
tial beneficial effects of bronchial thermoplasty 
provide the basis for mounting a placebo-con-
trolled trial involving the use of sham bronchial 
thermoplasty.
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